A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
Status:
Completed
Trial end date:
2020-01-07
Target enrollment:
Participant gender:
Summary
This is a multicenter, exploratory, randomized, double-blind study of the administration of
mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of
mavacamten doses titrated to achieve 1 of 2 target drug concentrations.